At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 42 enrolled
Drug / intervention
Camlipixant +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, 2-part, Open-label, Fixed-sequence Study Evaluating the Effect of Rifampin (Part 1) and Rabeprazole (Part 2) on the Pharmacokinetics of a Single Dose of Camlipixant (BLU-5937) 50 mg Tablet in Healthy Participants Under Fasting Conditions
In Brief
A Phase 1 clinical trial evaluating Camlipixant, Rabeprazole, and 1 other intervention for Cough and Healthy. Completed, enrolled 42 participants across 1 site.
Detailed Summary
This is a phase 1, 2-part, open-label, fixed-sequence study evaluating the effect of rifampin (part 1) and rabeprazole (part 2) on the pharmacokinetics of a single dose of camlipixant (BLU-5937) 50 mg tablet in healthy participants under fasting conditions.
Study Details
Timeline
Phase 1CompletedFinished
202420252026
First PostedJun 2023
Enrollment StartJun 2023
Primary CompletionAug 2023
TodayJul 2026
First PostedJun 12, 2023
Enrollment StartJun 21, 2023
Primary CompletionAug 8, 2023
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 3.1 years ago
Interventions
Camlipixantdrug
Camlipixant will be administered
Rabeprazoledrug
Rabeprazole will be administered
Rifampindrug
Rifampin will be administered.